Srilatha Edupuganti, MD
Associate Professor of Medicine
Emory University School of Medicine
BiographyDr. Edupuganti received her MD degree from Louisiana State University School of Medicine in New Orleans. She completed her residency in Internal Medicine at Parkland Memorial Hospital University of Texas Southwestern Medical Center, and her Infectious Diseases Fellowship at Emory University and the University of North Carolina, Chapel Hill School of Medicine. She also received a MPH in Epidemiology form the University of North Carolina School of Public Health. In September 2006, she joined the faculty of the Division of Infectious Diseases as a member of the Hope Clinic where vaccine clinical trials are conducted.
Dr. Edupuganti’s research interests are translational research in vaccines and vaccine development. She has been focused on HIV vaccine development for the past 6 years. She has been a site principal investigator/co-investigator for the Merck HIV vaccine protocols. She is a site investigator/co-investigator for the HIV Vaccine Trials Network (HVTN) protocols that are being conducted at the Hope clinic. She serves as the PI/Co-investigator for vaccine protocols that are conducted through the U19 funding mechanism where immunology to yellow fever vaccine, small pox vaccine and influenza vaccines are being studied. She is also a co-investigator for the vaccine protocols that are conducted through the Vaccine Trials Evaluation Unit (VTEU) network funded by DMID, NIH.
She is an attending physician at Grady Memorial Hospital.
She is involved in the teaching, administrative activities and conference of the Division of Infectious Diseases including lectures, interviews, journal club, case of the week and research seminars. At the Hope Clinic, she participates in the training of junior, international, and minority investigators in vaccine clinical trails methodologies, provides education, prevention, and community outreach services, which includes speaking to community and other groups.
Edupuganti S, Weber D, Hudgens M and Poole C. Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studies. HIV Clinical Trials. 5(5):259-268, 2004 Sept/Oct.